Home
>
US Stocks
>
BeyondSpring Inc
BeyondSpring Inc
BYSI

BeyondSpring Inc (BYSI)

$15.254.63%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$15.08
Today Low/High$14.89 / $15.42
52 Week Low/High$8.9 / $33
Market Cap$604.2M

Company Details

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.
OrganisationBeyondSpring Inc
Employees91
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is BeyondSpring Inc (BYSI) share price today?

Can Indians buy BeyondSpring Inc (BYSI) shares?

How can I buy BeyondSpring Inc (BYSI) shares from India?

Can Fractional shares of BeyondSpring Inc (BYSI) be purchased?

What are the documents required to start investing in BeyondSpring Inc (BYSI) stocks?

We are a SEBI registered investement advisor